Notably, the anticipated lower cytotoxicity of IMT is attributed to the observed lower expression levels of its primary targets, HIPK4 and SLC22A2, in bladder cancer compared to the targets of GCB and 5-FU. This evidence concerns the gene SLC22A2 and urinary bladder carcinoma.